Filter results
Type
Audience
Last updated
Topics
-
ATAGI recommendations on use of the Pfizer COVID-19 vaccine for children aged 6 months to 4 years
News and media9 June 2023 - Recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI) on the use of the Pfizer COVID-19 vaccine for children aged 6 months to 4 years (Pfizer 6 months to 4 years).
-
Budget 2019–20: Prioritising Mental Health – Perinatal Mental Health and Wellbeing Program
Resources › Publications31 March 2019 - This Budget fact sheet outlines how the Government will support the mental health of expectant and new parents through an innovative Perinatal Mental Health and Wellbeing Program.
-
COVID-19 vaccination – Pregnancy, Breastfeeding and the COVID-19 vaccines
Resources › Videos19 July 2022 - Information in Auslan for people with disability about pregnancy, breastfeeding and the COVID-19 vaccines.
-
Top 3 questions – What is long COVID, is it becoming more common, do vaccines reduce your chance of getting it
News and media20 May 2022 - Deputy Chief Medical Officer, Professor Michael Kidd, answers the Top Three questions across our channels.
-
Private health insurance clinical category definitions 6 July 2022
Resources › Publications4 March 2024 - Standard clinical category definitions for private health insurance hospital policies, effective 1 July 2022 and 6 July 2022.
-
Medical Research Future Fund Research Administration Officer Webinar – 27 March 2024
Resources › Videos17 May 2024 - In this video we answer research administration officers’ questions about Medical Research Future Fund (MRFF) grants. We also talk about impact evaluation and reporting.
-
Life Saving Drugs Program – Fabry disease – Medicines review protocol
Resources › Publications18 March 2019 - This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for Fabry disease.
-
Life Saving Drugs Program – Pompe disease – Medicines review protocol
Resources › Publications4 July 2019 - This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for Pompe disease.
-
Privacy notice for the National Epidermolysis Bullosa Dressing Scheme – patients
Using our websites › Website privacy policy15 February 2024 - Find out how we manage any personal information we collect about you when you apply for the National Epidermolysis Bullosa Dressing Scheme (NEBDS).
-
Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement
Resources › Publications2 February 2021 - This document states the outcome of Alexion Pharmaceuticals Australasia's application to include asfotase alfa on the Life Saving Drugs Program.